...
机译:在患有单一重新排列和截断的NF2 NF2基因的转移性尿路上皮癌的患者中对铂族疗法的长期反应
Division of Hematology‐Oncology Department of MedicineUniversity of Pittsburgh School of;
Foundation Medicine IncCambridge Massachusetts;
Foundation Medicine IncCambridge Massachusetts;
University of Pittsburgh Medical Center (UPMC) Hillman Cancer CenterPittsburgh Pennsylvania;
University of Pittsburgh Medical Center (UPMC) Hillman Cancer CenterPittsburgh Pennsylvania;
Division of Hematology‐Oncology Department of MedicineUniversity of Pittsburgh School of;
everolimus; FoundationOne; mTOR; NF2; sarcomatoid; urothelial carcinoma;
机译:在患有单一重新排列和截断的NF2 NF2基因的转移性尿路上皮癌的患者中对铂族疗法的长期反应
机译:atezolizumab患者患有铂化疗治疗后的局部晚期和转移性尿路上皮癌:单臂,多期,第2期试验
机译:回复:Atezolizumab在铂类化疗治疗后进展为局部晚期转移性尿路上皮癌的患者中:单臂,多中心,2期试验
机译:肌肉侵袭性尿路上皮癌新辅助化疗的蛋白质生物标志物的鉴定与验证
机译:运用统计学习理论评价转移性大肠癌患者的治疗反应和预测结局。
机译:Atezolizumab在局部晚期和转移性尿路上皮癌患者中的铂类化学疗法治疗后进展:单臂2期试验
机译:FGFR突变或基因融合患者转移性尿路上癌患者的预后作用,接受一线铂基化疗:大,单机构队列的结果